title: Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.
abstract: Data from randomized, controlled trials suggest that post-induction phase (IP) treatment with bevacizumab may benefit patients with advanced non-small-cell lung cancer (NSCLC). Real-world clinical practice, however, can involve variable use and patterns of treatment in broader patient populations. To assess the effect of bevacizumab on post-IP overall survival (OS) following IP chemotherapy + bevacizumab, analyses were conducted in patients enrolled in the Avastin(®) Registry--Investigation of Effectiveness and Safety (ARIES) observational cohort study (OCS) who received post-IP bevacizumab. ARIES was a large, prospective OCS of patients who received chemotherapy in combination with bevacizumab for the first-line treatment of NSCLC. This unplanned, post hoc analysis included patients who received chemotherapy and bevacizumab and who did not have progressive disease through the completion of IP treatment. A dichotomous analysis compared outcomes in patients who did and did not receive bevacizumab before a landmark date of day 30 post IP. A cumulative exposure analysis used a time-dependent Cox regression model to assess the effect of cumulative post-IP bevacizumab exposure on post-IP OS. In the dichotomous analysis, the duration of post-IP OS was significantly longer in patients who received post-IP bevacizumab; median post-IP OS was 15.6 vs. 11.3 months, respectively (hazard ratio [HR] = 0.80; 95 % confidence interval 0.71-0.91; P < 0.001). The cumulative exposure analysis observed that each additional cycle of cumulative bevacizumab exposure decreased the HR for post-IP OS by 2.7 %, on average. In conclusion, post-IP bevacizumab exposure was associated with improved post-IP OS in patients with advanced NSCLC who were enrolled in the ARIES OCS.
authors.affiliation: Scripps Clinic, 10666 N Torrey Pines Rd - MS217, La Jolla, CA, 92037, USA. mkosty@scripps.edu.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Kosty
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
authors.forename: Antoinette J
authors.initials: AJ
authors.lastname: Wozniak
authors.affiliation: The University of Miami Sylvester Cancer Center, Deerfield Beach, FL, USA.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Jahanzeb
authors.affiliation: Genentech, Inc., South San Francisco, CA, USA.
authors.forename: Larry
authors.initials: L
authors.lastname: Leon
authors.affiliation: Genentech, Inc., South San Francisco, CA, USA.
authors.forename: Susan
authors.initials: S
authors.lastname: Fish
authors.affiliation: Genentech, Inc., South San Francisco, CA, USA.
authors.forename: Sebastien J
authors.initials: SJ
authors.lastname: Hazard
authors.affiliation: Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Lynch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000068258:Bevacizumab
keywords: Bevacizumab; Non-small-cell lung cancer; Observational cohort study; Post-induction therapy